Hormone Therapy for Breast Cancer in India: Medicines, Duration, Side Effects and Cost

After a breast cancer diagnosis, patients often hear doctors discuss hormone receptor testing. If the cancer is hormone receptor-positive, the oncologist may recommend hormone therapy as part of the treatment plan.

Unlike chemotherapy, which uses medicines to destroy rapidly dividing cells, hormone therapy works by blocking the effects of hormones or reducing the body's hormone production. For many patients it is an important part of long-term treatment after surgery, and it can also help control selected advanced hormone receptor-positive cancers.

Common medicines include tamoxifen, letrozole, anastrozole and exemestane. Some premenopausal patients may also need ovarian suppression. Treatment can continue for five years or longer, depending on recurrence risk and tolerance.

GAF planning for hormone therapy is $1,000–$4,500 (outpatient · often years of tablets). Related reading includes the existing hormone therapy overview, hormone therapy side effects, ER, PR and HER2 results and targeted therapy for breast cancer when CDK4/6 inhibitors are considered.

Named medical oncologists and medical oncology hospitals can be filtered by city before travel.

Hormone therapy, also called endocrine therapy, treats breast cancers that depend on hormones such as oestrogen or progesterone to grow. It works by blocking the effect of hormones on cancer cells or reducing the amount of oestrogen available to stimulate hormone-sensitive cells.

It can help reduce recurrence risk after surgery and may slow or control hormone receptor-positive disease that has spread. It is not hormone replacement therapy used for menopausal symptoms. Patients with hormone-sensitive breast cancer should discuss any hormonal treatment with their oncologist.

Hormone therapy is generally considered when pathology shows ER-positive and/or PR-positive disease. The report usually also includes HER2 status, tumour grade and other findings — explained further in the diagnosis guide and ER, PR and HER2 guide.

ER-positive cancers have oestrogen receptors that can respond to oestrogen. PR-positive cancers have progesterone receptors. Together these results guide endocrine treatment selection.

Some tumours are both hormone receptor-positive and HER2-positive. Treatment may combine surgery, chemotherapy, HER2-targeted medicines, radiation and hormone therapy. See HER2-positive breast cancer treatment for the HER2 pathway.

Triple-negative breast cancer is negative for ER, PR and HER2. Conventional endocrine therapy is generally not effective. Other treatments such as chemotherapy and selected immunotherapy may be considered instead.

Endocrine medicines reduce the ability of hormone-sensitive cancer cells to use oestrogen, or reduce the body's oestrogen production. Main groups include selective oestrogen receptor modulators (SERMs), aromatase inhibitors (AIs), ovarian function suppression and, in certain advanced settings, selective oestrogen receptor degraders (SERDs).

Choice depends on menopausal status, stage, previous treatment, recurrence risk and other medical factors. Broader sequencing sits on breast cancer treatment options and breast cancer stages.

Tamoxifen blocks the effect of oestrogen in breast tissue. It may be prescribed for premenopausal women, selected postmenopausal women, patients who cannot take an aromatase inhibitor, and certain advanced hormone receptor-positive settings.

A common initial duration is five years; some patients continue up to ten years. Selected patients may later switch to an aromatase inhibitor after menopause.

Aromatase inhibitors reduce oestrogen production and are commonly used in postmenopausal patients. The three commonly used medicines are letrozole, anastrozole and exemestane.

Before menopause the ovaries are a major oestrogen source. After menopause, aromatase activity in other tissues continues to produce smaller amounts of oestrogen. That difference drives medicine choice.

Aromatase inhibitors should not be used alone while ovaries are still functioning.

Ovarian suppression reduces or stops ovarian oestrogen production for selected higher-risk premenopausal patients. It may be combined with tamoxifen or an aromatase inhibitor.

It is not necessary for every premenopausal patient. Factors include age, nodes, grade and other high-risk features.

Patients who may want children should discuss fertility preservation before starting treatment.

For many early-stage hormone receptor-positive cancers, treatment lasts at least five years. Selected higher-risk patients may benefit from continuing up to ten years because late recurrence remains possible.

Extended therapy is not automatically better for everyone. Tumour size, nodes, grade, receptor expression, menopausal status, bone health, side effects, age and comorbidities all matter.

Yes, in selected plans — for example tamoxifen for two to three years then an aromatase inhibitor, the reverse sequence, or tamoxifen for five years followed by an aromatase inhibitor. Patients should not switch independently.

In selected hormone receptor-positive advanced disease, endocrine therapy aims to control cancer, relieve symptoms and maintain quality of life. For many HR-positive, HER2-negative metastatic cases, endocrine therapy may be combined with a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib).

Those targeted medicines are covered in the targeted therapy for breast cancer guide and the targeted therapy cost sheet. Other options may include fulvestrant, everolimus in selected settings, other targeted medicines or chemotherapy when indicated.

Fulvestrant is a selective oestrogen receptor degrader given by injection in certain advanced hormone receptor-positive settings, alone or with selected targeted medicines. It is not the same as tamoxifen or an aromatase inhibitor.

Endocrine therapy usually does not cause the same hair loss, nausea or blood-count drops associated with many chemotherapy regimens, but long-term symptoms can affect daily life.

More detail sits on hormone therapy side effects.

Do not stop endocrine therapy without speaking to the oncologist. Supportive care, switching medicines or adjusting the plan may help.

Do not start supplements, herbal products or hormonal preparations without checking with the oncologist.

Bone health is especially important on aromatase inhibitors or ovarian suppression. Monitoring may include DEXA scanning, fracture-risk assessment, calcium and vitamin D review when appropriate, activity advice and bone-protective medicines such as bisphosphonates or denosumab in selected cases.

Occasional missed doses happen, but repeated gaps reduce adherence. Follow the medicine instructions and ask what to do after a missed dose. Do not take extra tablets to compensate unless specifically instructed. If side effects are the barrier, discuss alternatives rather than stopping silently.

Cost depends on medicine, brand, dosage, duration and whether injections or extra monitoring are required. Many endocrine medicines have generic formulations that can make long-term treatment more affordable than some injectable or targeted regimens — but there is no single price for every plan.

These GAF figures are partner planning ranges from the live cost sheets — not hospital quotations. Wider pathway context sits on breast cancer treatment cost in India.

Unlike surgery or radiation, endocrine therapy is often continued after returning home. Share biopsy and histopathology, ER/PR/HER2 results, stage, surgical pathology, prior chemo/radiation summaries, current medicines, medical history and bone-density reports when available.

Practical travel sequencing is covered in breast cancer treatment in India for international patients. City filters for Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad medical oncologists help shortlist campuses.

Before leaving India, obtain medicine names and doses, duration, injection schedules, monitoring needs, side-effect guidance and follow-up timing for the local oncologist.

Hormone therapy is a treatment that blocks the effects of hormones or reduces their production. It is used for breast cancers that are sensitive to oestrogen or progesterone.

No. It is generally used for hormone receptor-positive breast cancer. Patients with hormone receptor-negative disease usually do not benefit from conventional endocrine treatment.

Tamoxifen, letrozole, anastrozole and exemestane are commonly used medicines. The choice depends on menopausal status, cancer stage and recurrence risk.

Tamoxifen can be used in both premenopausal and selected postmenopausal patients.

An aromatase inhibitor such as letrozole should not be used alone in a woman with functioning ovaries. It may be used with ovarian suppression in selected patients.

Many patients receive at least five years of treatment. Selected patients at higher risk of recurrence may benefit from treatment lasting up to ten years.

Significant hair loss is not typical in the same way as with many chemotherapy regimens. Some patients may experience hair thinning, depending on the medicine.

Some patients report weight changes during treatment. Age, menopause, activity levels, sleep, diet and other treatments may also contribute. Discuss unexplained or significant weight changes with the medical team.

The treatment sequence depends on the clinical plan. Adjuvant endocrine therapy is commonly started after chemotherapy when chemotherapy is required. It may be given alongside certain other treatments under specialist guidance.

Some patients complete treatment after five years, while others may benefit from longer treatment. The decision depends on recurrence risk, side effects and the patient's overall health.

No. Hormone therapy for breast cancer blocks hormone activity or reduces hormone production. Hormone replacement therapy is used to treat hormonal symptoms and requires special caution in patients with hormone-sensitive breast cancer.

GAF planning for hormone therapy is $1,000–$4,500. Exact expense depends on the prescribed medicine, brand, treatment duration and whether injections or additional monitoring are required.

In many cases, oral hormone therapy can be continued under the supervision of a local oncologist. Patients should carry a detailed treatment summary and follow-up plan.

Ovarian suppression reduces ovarian oestrogen production using injections, surgery or rarely radiation. It may be added for selected higher-risk premenopausal patients.

Lowering oestrogen can reduce bone density. DEXA scanning, lifestyle measures and bone-protective medicines may be recommended for selected patients.

Follow the medicine instructions and ask the doctor or pharmacist. Do not double doses unless specifically instructed. Persistent side effects need a medical review rather than silent discontinuation.

Hormone therapy is an important part of treatment for many patients with hormone receptor-positive breast cancer. Tamoxifen, letrozole, anastrozole and exemestane help reduce the effect or production of oestrogen. Some premenopausal patients also need ovarian suppression.

Treatment commonly continues for at least five years, and selected patients may benefit from longer therapy. Side effects, bone health, menopausal status and adherence all need attention. The best plan provides appropriate cancer control while remaining manageable over time.

Medical disclaimer: This article is for educational purposes and does not replace consultation with a qualified medical oncologist. The choice of endocrine medicine, ovarian suppression, treatment duration and monitoring must be based on the patient's pathology, menopausal status, recurrence risk and overall health. Patients should not stop or change prescribed medicines without medical advice.